Zejula (niraparib) — Medica

Initial criteria

• Patient is age ≥ 18 years
• Patient has BRCA2-altered disease
• Patient has tried one systemic regimen (e.g., dacarbazine, docetaxel, doxorubicin, gemcitabine, ifosfamide, Yondelis [trabectedin])

Approval duration

1 year